Company record
A clear public starting point.
This page gathers the company’s published description, taxonomy, status, and official link in one place. It does not make claims about private activity or deal terms.
Startup in Sahin’s portfolio

Generative AI and physics-based modeling to design cyclic peptide drugs
| Round | Raised | Date |
|---|---|---|
| Seed | — | 2023-06-13 |
| Seed | $4M | 2020-06-30 |
| Accelerator/Incubator | $150K | 2020-03-18 |
| Accelerator/Incubator | $205K | 2019-12-20 |
Total raised: $4M
Menten AI designs peptide drugs with generative AI combined with physics-based models. Its MAUD platform designs ring-shaped peptides for hard drug targets.
Source: Menten AI
Hans Melo is the co-founder and CEO of Menten AI, and Vikram Mulligan is its academic co-founder. Both hold PhDs.
Source: Menten AI
Menten AI lists Bristol Myers Squibb as one of its pharmaceutical partners. It says it works with several of the ten largest drugmakers.
Source: Menten AI
As an angel investor in 231 startups across 14 categories, I look for companies with exceptional founders, large addressable markets, and clear competitive advantages. MENTEN AI stood out in the Biotech space.
Company record
This page gathers the company’s published description, taxonomy, status, and official link in one place. It does not make claims about private activity or deal terms.